STAT stories you may have missed
Steve Woit runs an exclusive, confidential club for biotech CEOs — but it’s not filled with the Arturo Fuente cigars and $30 martinis you might expect. It’s more “group therapy,” he says.
Two of the Ebola therapies tested in the current outbreak in the Democratic Republic of the Congo dramatically reduced the risk of dying from the disease, per final data from a landmark clinical trial.
Biogen will give a health plan larger discounts when patients report its multiple sclerosis drugs, Tecfidera and Avonex, don't work. (Or, for D.C. nerds: a story of patient-reported outcomes meeting value-based contracting.)
How exactly did Bluebird Bio decide on pricing for its gene therapy, Zynteglo? The company’s top exec tells the story.
Building a health-technology startup on nothing but hot air may be easier than you’d think — at least, according to a federal indictment unsealed Monday.
ICYMI: How a billionaire couple greased the skids for Nancy Pelosi’s drug pricing bill.
Biogen will give a health plan larger discounts when patients report its multiple sclerosis drugs, Tecfidera and Avonex, don't work. (Or, for D.C. nerds: a story of patient-reported outcomes meeting value-based contracting.)
How exactly did Bluebird Bio decide on pricing for its gene therapy, Zynteglo? The company’s top exec tells the story.
Building a health-technology startup on nothing but hot air may be easier than you’d think — at least, according to a federal indictment unsealed Monday.
ICYMI: How a billionaire couple greased the skids for Nancy Pelosi’s drug pricing bill.
.png)
No hay comentarios:
Publicar un comentario